logo
logooffcanvas
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS;  AND SUICIDAL THOUGHTS AND BEHAVIORS
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for use in patients with dementia-related psychosis.
  • Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. LATUDA is not approved for use in patients under the age of 18 years.

 

Warning: Asthma-Related Death

Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including arformoterol, the active ingredient in BROVANA (see WARNINGS). The safety and efficacy of BROVANA in patients with asthma have not been established. All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS).

Connect With Sunovion
 Call (888) 394-7377
or
 Submit A Medical Inquiry

LUNESTA,, XOPENEX HFA, and BROVANA are registered trademarks of Sunovion Pharmaceuticals Inc., and ALVESCO, OMNARIS and ZETONNA are registered trademarks of Takeda GmbH, used under license. APTIOM under license from  . LATUDA, SUNOVION and are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.

This site contains information intended for U.S. healthcare professionals only.

© 2015 Sunovion Pharmaceuticals Inc. All rights reserved. 6/15 SUN013-15